Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 7/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.34 |
| ▸ | ITGAV | P06756 | 4/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073055 | 0.99 | ITGB3 (0.33) | PPARDITGB3ITGAVITGA2BITGB1 | |
| SCHEMBL7073042 | 0.97 | ITGB3 (0.36) | PPARDITGB3ITGAVITGA2BITGB1 | |
| SCHEMBL7075503 | 0.80 | PPARD (0.40) | PPARDITGB3ITGAVITGA2BITGB1 | |
| SCHEMBL7071285 | 0.77 | ITGB3 (0.42) | PPARDITGB3ITGAVITGA2BITGB1 | |
| SCHEMBL7073036 | 0.76 | ITGB3 (0.30) | PPARDITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL7071498 | 0.76 | ITGB3 (0.42) | PPARDITGB3ITGAVITGA2BITGB1 | |
| Trifluoroacetic Acid SCHEMBL7078541 | 0.75 | ITGB3 (0.41) | PPARDITGB3ITGAVITGA2BITGB1 | |
| Trifluoroacetic Acid SCHEMBL7078808 | 0.75 | ITGB3 (0.41) | PPARDITGB3ITGAVITGA2BITGB1 | |
| Hydrochloric Acid SCHEMBL7071458 | 0.73 | ITGB3 (0.40) | PPARDITGB3ITGAVITGA2BITGB1 | |
| Hydrochloric Acid SCHEMBL7075240 | 0.72 | SMYD3 (0.42) | ITGB3ITGA2BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | claimed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | claimed |
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | PPARD 3395/4885ITGB3 3/4885ITGAV 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.